Literature DB >> 23547179

Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases.

Robert S Kumar1, Pamela S Douglas, Eric D Peterson, Kevin J Anstrom, David Dai, J Matthew Brennan, Peter Y M Hui, Michael E Booth, John C Messenger, Richard E Shaw.   

Abstract

BACKGROUND: Black, Hispanic, and Asian patients have been underrepresented in percutaneous coronary intervention clinical trials; therefore, there are limited data available on outcomes for these race/ethnicity groups. METHODS AND
RESULTS: We examined outcomes in 423 965 patients in the National Cardiovascular Data Registry CathPCI Registry database linked to Medicare claims for follow-up. Within each race/ethnicity group, we examined trends in drug-eluting stent (DES) use, 30-month outcomes, and relative outcomes of DES versus bare metal stents. Overall, 390 351 white, 20 191 black, 9342 Hispanic, and 4171 Asian patients > 65 years of age underwent stent implantation from 2004 through 2008 at 940 National Cardiovascular Data Registry participating sites. Trends in adoption of DES were similar across all groups. Relative to whites, black and Hispanic patients undergoing percutaneous coronary intervention had higher long-term risks of death and myocardial infarction (blacks: hazard ratio, 1.28; 95% confidence interval, 1.24-1.32; Hispanics: hazard ratio, 1.15; 95% confidence interval, 1.10-1.21). Long-term outcomes were similar in Asians and whites (hazard ratio, 0.99; 95% confidence interval, 0.92-1.08). Use of DES was associated with better 30-month survival and lower myocardial infarction rates compared with the use of bare metal stents among all race/ethnicity groups except Hispanics, who had similar outcomes with DES or bare metal stents.
CONCLUSIONS: Black and Hispanic patients undergoing percutaneous coronary intervention had worse long-term outcomes relative to white and Asian patients. Compared with bare metal stent use, DES use was generally associated with superior long-term outcomes in all racial and ethnic groups, although these differences were not statistically significant in Hispanic patients.

Entities:  

Mesh:

Year:  2013        PMID: 23547179     DOI: 10.1161/CIRCULATIONAHA.113.001437

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.

Authors:  Glenn N Levine; Young-Hoon Jeong; Shinya Goto; Jeffrey L Anderson; Yong Huo; Jessica L Mega; Kathryn Taubert; Sidney C Smith
Journal:  Nat Rev Cardiol       Date:  2014-08-26       Impact factor: 32.419

Review 2.  The current state of ethnic and racial disparities in cardiovascular care: lessons from the past and opportunities for the future.

Authors:  Jennifer Lewey; Niteesh K Choudhry
Journal:  Curr Cardiol Rep       Date:  2014       Impact factor: 2.931

3.  "East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome.

Authors:  Young-Hoon Jeong
Journal:  Curr Cardiol Rep       Date:  2014-05       Impact factor: 2.931

Review 4.  Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.

Authors:  Eden Liu; Leon Hsueh; Hajwa Kim; Mladen I Vidovich
Journal:  Am Heart J       Date:  2017-09-08       Impact factor: 4.749

5.  Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation: Insights and Results From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study Pooled Analysis.

Authors:  Wayne Batchelor; David E Kandzari; Scott Davis; Luis Tami; John C Wang; Islam Othman; Osvaldo S Gigliotti; Amir Haghighat; Sarabjeet Singh; Mario Lopez; Gregory Giugliano; Phillip A Horwitz; Jaya Chandrasekhar; Paul Underwood; Craig A Thompson; Roxana Mehran
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

6.  Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial.

Authors:  Ana M Palacio; Claudia Uribe; Leslie Hazel-Fernandez; Hua Li; Leonardo J Tamariz; Sylvia D Garay; Olveen Carrasquillo
Journal:  J Gen Intern Med       Date:  2014-12-13       Impact factor: 5.128

7.  Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals.

Authors:  Taisei Kobayashi; Thomas J Glorioso; Ehrin J Armstrong; Thomas M Maddox; Mary E Plomondon; Gary K Grunwald; Steven M Bradley; Thomas T Tsai; Stephen W Waldo; Sunil V Rao; Subhash Banerjee; Brahmajee K Nallamothu; Deepak L Bhatt; A Garvey Rene; Robert L Wilensky; Peter W Groeneveld; Jay Giri
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

8.  Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.

Authors:  Bin Wu; Ruoyan Gai Tobe; Yuchen Liu; Ben He
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

9.  Racial and sex disparities in resource utilization and outcomes of multi-vessel percutaneous coronary interventions (a 5-year nationwide evaluation in the United States).

Authors:  Rupak Desai; Sandeep Singh; Hee Kong Fong; Hemant Goyal; Sonu Gupta; Dipen Zalavadia; Rajkumar Doshi; Sejal Savani; Samir Pancholy; Rajesh Sachdeva; Gautam Kumar
Journal:  Cardiovasc Diagn Ther       Date:  2019-02

10.  Factors Associated with the Use of Drug-Eluting Stents in Patients Presenting with Acute ST-Segment Elevation Myocardial Infarction.

Authors:  Jose F Chavez; Jacob A Doll; Anuj Mediratta; Francesco Maffessanti; Janet Friant; Jonathan D Paul; John E A Blair; Sandeep Nathan; Neeraj Jolly; Atman P Shah
Journal:  Cardiol Res Pract       Date:  2015-05-28       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.